MedTrace Logo

Inhalation Flow Rate-study

NCT02563197 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-04-26

No results posted yet for this study

Summary

Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.

Conditions

Interventions

DEVICE

T-326 Inhaler

No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2016-02-17
Completion
2016-04-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02563197 on ClinicalTrials.gov